Your browser doesn't support javascript.
loading
HLA-G expression in melanomas.
Marletta, Stefano; Girolami, Ilaria; Munari, Enrico; Pantanowitz, Liron; Bernasconi, Riccardo; Torresani, Evelin; Brunelli, Matteo; Eccher, Albino.
Afiliación
  • Marletta S; Department of Pathology and Diagnostics, Section of Pathology, University Hospital of Verona, Verona, Italy.
  • Girolami I; Division of Pathology, Central Hospital, Bolzano, Italy.
  • Munari E; Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
  • Pantanowitz L; Department of Pathology & Clinical Labs, University of Michigan, Ann Arbor, MI, USA.
  • Bernasconi R; Department of Pathology and Diagnostics, Section of Pathology, University Hospital of Verona, Verona, Italy.
  • Torresani E; Department of Pathology and Diagnostics, Section of Pathology, University Hospital of Verona, Verona, Italy.
  • Brunelli M; Department of Pathology and Diagnostics, Section of Pathology, University Hospital of Verona, Verona, Italy.
  • Eccher A; Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy.
Int Rev Immunol ; 40(5): 330-343, 2021.
Article en En | MEDLINE | ID: mdl-33426980
OBJECTIVE: Human leukocyte antigen G (HLA-G) is a non-classical HLA class I molecule involved in inducing tolerance at the feto-maternal interface and in escape of immune response by tumor cells. The aim of the study is to review the published literature on the expression of HLA-G in malignant melanomas and its clinicopathological and prognostic correlates. METHODS: A systematic search was carried out in electronic databases. Studies dealing with HLA-G expression in surgically-removed human samples were retrieved and analyzed. RESULTS: Of 1737 retrieved articles, 16 were included. The main themes regarded HLA-G expression in malignant melanocytic lesions, assessed by immunohistochemistry (IHC), soluble or molecular techniques, and its relationship with clinicopathological features, such as tumor thickness and malignant behavior. Overall significant HLA-G expression was found in 460/843 tumors (55%), and specifically in 251/556 melanomas (45%) evaluated with IHC, in 208/250 cases (83%) examined with soluble methods and in 13/23 melanoma lesions (57%) tested with polymerase chain reaction. Despite the correlation with parameters indicating an aggressive behavior, no studies demonstrated any prognostic value of HLA-G expression. Furthermore, uveal melanomas were constantly negative for this biomarker. CONCLUSION: Overall, published data indicate that while HLA-G is involved in the interactions between melanomas and the immune system, it is unlikely to be the only factor to play such a role, therefore making it difficult to designate it as a prognostically relevant molecule. Evidence further suggests that HLA-G is not implicated in the immunobiology of uveal melanomas.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Úvea / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Int Rev Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Úvea / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Int Rev Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Italia